Los Angeles Capital Management LLC Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Los Angeles Capital Management LLC cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 40.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,117 shares of the biopharmaceutical company’s stock after selling 50,284 shares during the period. Los Angeles Capital Management LLC’s holdings in TG Therapeutics were worth $2,201,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares in the last quarter. Synergy Asset Management LLC bought a new stake in TG Therapeutics in the 4th quarter valued at $75,000. GAMMA Investing LLC lifted its stake in TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 2,171 shares in the last quarter. KBC Group NV boosted its holdings in shares of TG Therapeutics by 30.5% during the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,092 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of TG Therapeutics during the third quarter valued at about $111,000. 58.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is owned by insiders.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $28.53 on Friday. The business’s 50 day moving average price is $30.79 and its 200-day moving average price is $27.98. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $36.84. The company has a market cap of $4.44 billion, a P/E ratio of -285.27 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.